DCLK2: A Potential Drug Target and Biomarker (G166614)

Target Name: DCLK2

NCBI ID: G166614

DCLK2

DCLK2: A Potential Drug Target and Biomarker

DCLK2 (doublecortin-like kinase 2) is a protein that is expressed in various tissues, including the brain, pancreas, and peripheral tissues. It is a member of the superfamily of kinases, which includes proteins that play a crucial role in cell signaling pathways. The function of DCLK2 is not well understood, but it is known to be involved in several cellular processes, including cell growth, differentiation, and survival.

DCLK2 as a Potential Drug Target

DCLK2 has been identified as a potential drug target due to its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One of the reasons for its potential as a drug target is its unique structure, which allows it to interact with various signaling molecules. DCLK2 has four transmembrane domains and a unique N-terminus that contains a conserved Asp229 residue. This conserved residue is known to be involved in protein-protein interactions and is a potential target for small molecules.

Another reason for DCLK2's potential as a drug target is its unique expression pattern. DCLK2 is highly expressed in several tissues, including the brain, and its levels are often increased in diseases, such as cancer and neurodegenerative diseases. This makes it a potential biomarker for these diseases. Additionally, DCLK2 has been shown to be involved in several signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival. This suggests that DCLK2 may be a useful target for drugs that are designed to modulate these signaling pathways.

DCLK2 as a Biomarker

DCLK2 has also been shown to be involved in several biomarker studies. For example, researchers have used DCLK2 as a biomarker for several types of cancer, including breast, ovarian, and colorectal cancers. They have found that DCLK2 levels are often increased in these cancers and that inhibiting DCLK2 activity may be a useful approach for cancer treatment.

In addition to its potential as a cancer biomarker, DCLK2 has also been shown to be involved in several other biomarker studies. For example, DCLK2 has been used as a biomarker for neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Researchers have found that DCLK2 levels are often increased in these diseases and that inhibiting DCLK2 activity may be a useful approach for disease treatment.

DCLK2 as a Potential Drug

DCLK2 has also been identified as a potential drug target for several reasons. One of the main reasons is its involvement in several cellular processes that are important for human health, such as cell growth, differentiation, and survival. Additionally, DCLK2 has a unique structure that allows it to interact with various signaling molecules, making it a potential target for small molecules.

Another reason for DCLK2's potential as a drug is its unique expression pattern. DCLK2 is highly expressed in several tissues, including the brain, and its levels are often increased in diseases, such as cancer and neurodegenerative diseases. This makes it a potential biomarker for these diseases and a potential target for drugs that are designed to treat them.

Conclusion

DCLK2 is a protein that has been shown to be involved in several cellular processes, including cell growth, differentiation, and survival. Its unique structure and expression pattern make it a potential drug target and biomarker for several diseases. In the future, research into the function of DCLK2 and its potential as a drug

Protein Name: Doublecortin Like Kinase 2

Functions: Protein kinase with a significantly reduced C(a2+)/CAM affinity and dependence compared to other members of the CaMK family. May play a role in the down-regulation of CRE-dependent gene activation probably by phosphorylation of the CREB coactivator CRTC2/TORC2 and the resulting retention of TORC2 in the cytoplasm (By similarity)

The "DCLK2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DCLK2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets